122 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
Rank Status Study
1 Available Omegaven Expanded Access Protocol
Condition: Parenteral Nutrition Associated Liver Disease
Intervention: Drug: Omegaven
2 Available An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Condition: Differentiated Thyroid Cancer
Intervention: Drug: Lenvatinib
3 Available Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome
Condition: Dravet Syndrome
Intervention: Drug: Stiripentol
4 Available Compassionate Use of Stiripentol in Dravet Syndrome
Condition: Dravet Syndrome
Intervention: Drug: Stiripentol
5 Available INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis (PMF);   Post Polycythemia Myelofibrosis (PPV MF);   Post-essential Thrombocythemia Myelofibrosis (PET-MF);   Myelofibrosis;   Post Polycythemia Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Intervention: Drug: INC424
6 Available To Validate the Specific Patterns of Magnetocardiography, a Non-invasive Non-contact Examination for Patients With Ischemic Heart Disease or Cardiac Arrhythmia
Condition: Arrhythmia
Intervention: Other: MCG
7 Available The Effect of Adding Magnesium Sulfate to Standard Epidural and Interscalene Block in Treatment of Patients With Chronic Pain
Condition: Pain
Intervention: Drug: Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain
8 Available An Extended Access Program for Perampanel
Condition: Partial Onset Seizures
Intervention: Drug: Perampanel
9 Available Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease
Conditions: Cholestasis;   Short Bowel Syndrome
Intervention: Drug: Omegaven
10 Available 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
Conditions: Lambert-Eaton Myasthenic Syndrome (LEMS);   Congenital Myasthenia (CM)
Intervention: Drug: 3,4-diaminopyridine
11 Available Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Condition: Chronic Myeloid Leukemia
Intervention: Drug: bosutinib
12 Available Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 DAP
13 Available 131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Pheochromocytoma
Conditions: Neuroblastoma;   Childhood Metastatic Pheochromocytoma
Interventions: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG);   Drug: 131 I-MIBG
14 Unknown  The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib and Imatinib
15 Available Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer
Condition: Gastric Cancer.
Intervention: Drug: Phase I Dose-finding Study of Sorafenib Study
16 Unknown  HIV-discordant Couple Intrauterine Insemination
Conditions: Infertility;   HIV Infections
Interventions: Other: Sperm washing and testing for HIV contamination;   Procedure: Intrauterine Insemination
17 Unknown  Second Line Therapy to Treat Age-Related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself
Condition: Age Related Macular Degeneration
Interventions: Drug: Visudyne;   Drug: Lucentis;   Drug: Dexamethasone
18 Available Prevention of Transmission of Sexually Transmitted Diseases in the Youth Through Effective Intervention,
Condition: HIV
Intervention: Behavioral: Lifestyle Counseling
19 Available Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage
Condition: Cholestasis of Parenteral Nutrition
Intervention: Drug: Omegaven 10%
20 Available Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants
Conditions: Hematologic Malignancies;   Inborn Errors of Metabolism Disorders;   Immune Deficiencies
Intervention: Biological: CliniMACS CD34 Reagent System

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years